ライフサイエンスコーパス: deoxythymidine

1 reverse transcriptase inhibitor 3'-azido-3'-deoxythymidine.

2 stable triplexes than did TFOs containing 2'-deoxythymidine.

3 in the presence of drugs [e.g., 3'-azido-3'-deoxythymidine, (-)2/,3'-dideoxy-3'-thiacytidine, hydrox

4 ine; 2'3'-dideoxyinosine; 2', 3'-didehydro-3'deoxythymidine; 2',3'-dideoxy-3'-thiacytidine; and 4-[2-

5 When 2'-deoxythymidine-3',5'-cyclic diphosphate, or the cyclic p

6 ated using thymidine 5'-triphosphate (dTTP), deoxythymidine 5'-(beta, gamma-methylenetriphosphate)(dT

7 se beta-DNA template-primer-chromium(III).2'-deoxythymidine 5'-beta,gamma-methylenetriphosphate [Cr(I

8 ases show identical binding to a 3'-azido-3'-deoxythymidine 5'-monophosphate (AZTMP)-terminated prime

9 plication fidelity, particularly for thymine-deoxythymidine 5'-monophosphate (T-dTMP) but not adenine

10 wild type TS but is converted to 3-methyl 2'-deoxythymidine 5'-monophosphate by many TS Asn 229 mutan

11 '-deoxyuridine 5'-monophosphate (dUMP) to 2'-deoxythymidine 5'-monophosphate.

12 o describe aqueous ionization energies of 2'-deoxythymidine 5'-phosphate (5'-dTMP-) and 2'-deoxycytid

13 generation of DNA precursors in the form of deoxythymidine 5'-phosphate is particularly important fo

14 idine 5'-triphosphate (dTTP) and 3'-azido-3'-deoxythymidine 5'-triphosphate (AZTTP) by wild-type HIV-

15 examine the binding and incorporation of 2'-deoxythymidine 5'-triphosphate (dTTP) and 3'-azido-3'-de

16 ribonucleotide in the syn conformation and a deoxythymidine 5'-triphosphate (dTTP), and that the fit

17 hod is presented for the determination of 2'-deoxythymidine 5'-triphosphate and 2'-deoxycytidine 5'-t

18 ucleoside triphosphates, such as 3'-azido-3'-deoxythymidine 5'-triphosphate and 3'-deoxythymidine 5'-

19 ido-3'-deoxythymidine 5'-triphosphate and 3'-deoxythymidine 5'-triphosphate, can also penetrate the v

20 c pathway, deoxycytidine 5'-triphosphate and deoxythymidine 5'-triphosphate, which act as an activato

21 The increase in deoxythymidine 5'-triphosphate-G mispairs was confirmed

22 n-Crick-like pairing between O(6)-MeG and 2"-deoxythymidine-5"-[(alpha, beta)-imido]triphosphate (app

23 orporated dA or dT opposite 1,N(6)-dA and 2'-deoxythymidine-5'-[(alpha,beta)-imido]triphosphate oppos

24 , which increases the excision of 3-azido-3'-deoxythymidine-5'-monophosphate (AZTMP) in vitro and inc

25 ate synthase reaction within the crystal, 2'-deoxythymidine-5'-monophosphate and 7,8-dihydrofolate, s

26 of the intermediate to form the product, 2'-deoxythymidine-5'-monophosphate.

27 rate (and/or not excise) the dTTP analog, 2'-deoxythymidine-5'-O-(alpha-phosphonomethyl)-beta, gamma-

28 thesize 5'-P(alpha)-boranodiphosphates of 2'-deoxythymidine, adenosine, guanosine, and uridine.

29 ral effect of stavudine (2', 3'-didehydro-3'-deoxythymidine) against human immunodeficiency virus (HI

30 ts, the thymidine analogs 3'-(18)F-fluoro-3'-deoxythymidine and (18)F-1-(2'-deoxy-2'-fluoro-beta-d-ar

31 he anti-HIV nucleoside analogues 3'-azido-3'-deoxythymidine and 2',3'-didehydro-2', 3'-dideoxythymidi

32 nferred high-level resistance to 3'-azido-3'-deoxythymidine and 2,3-didehydro-2,3-dideoxythymidine by

33 Beta-D-2',3'-Didehydro-3'-deoxythymidine and beta-D-2'-ara-fluoro-2',3'-dideoxyade

34 It is capable of phosphorylating deoxythymidine and deoxyuridine as does human thymidine

35 sly described for dCTP, protonation of N3 in deoxythymidine and not deoxycytidine would facilitate hy

36 A with a ribouridine in lieu of the critical deoxythymidine and show that this substitution results i

37 No reactivity was observed between deoxythymidine and the sugars.

38 s of two NRTIs, zidovudine [AZT (3'-azido-3'-deoxythymidine)] and didanosine [ddI (2',3'-dideoxyinosi

39 alues for adenosine, guanosine dihydrate, 2'-deoxythymidine, and cytidine are measured on natural abu

40 Deoxyguanosine, deoxyadenosine, deoxythymidine, and deoxycytidine were used as the model

41 ubstrates containing 3'-deoxyadenosine or 3'-deoxythymidine at specific sites and acceptor oligonucle

42 s was stalled by the presence of 3'-azido-3'-deoxythymidine at the primer terminus, possibly contribu

43 served in HBV-infected patients, 3' azido-3'-deoxythymidine (AZT [zidovudine]) had no effect on WHV r

44 Photoaffinity labeling with the 3'-azido-3'-deoxythymidine (AZT) analog 3',5-diazido-2', 3'-dideoxyu

45 3'-Azido-3'-deoxythymidine (AZT) and 3'-deoxythymidine (ddT) were ch

46 reverse transcriptase inhibitor 3'-azido-3'-deoxythymidine (AZT) and by mutation of the integrase ge

47 by augmented phosphorylation of 3'-azido-3'-deoxythymidine (AZT) and concomitantly greater sensitivi

48 also phenotypically resistant to 3'-azido-3'-deoxythymidine (AZT) and to the combination of 3TC and A

49 ur laboratory have characterized 3'-azido-3'-deoxythymidine (AZT) as a potent inhibitor of glycosphin

50 of phosphoramidate monoesters of 3'-azido-3'-deoxythymidine (AZT) bearing aliphatic amino acid methyl

51 hat antiretroviral drugs such as 3'-azido-3'-deoxythymidine (AZT) can influence the in vivo mutation

52 n domain increased resistance to 3'-azido-3'-deoxythymidine (AZT) from 11-fold to as much as 536-fold

53 fied as conferring resistance to 3'-azido-3'-deoxythymidine (AZT) in Escherichia coli.

54 and to test our hypothesis that 3'-azido-3'-deoxythymidine (AZT) increases the retroviral mutation r

55 e analogues ganciclovir (GCV) and 3'-azido-3'deoxythymidine (AZT) into their active, cytotoxic forms.

56 The resistance of HIV-1 to 3'-azido-3'-deoxythymidine (AZT) involves phosphorolytic excision of

57 ency virus (HIV) 1 resistance to 3'-azido-3'-deoxythymidine (AZT) involves reverse transcriptase (RT)

58 vity of the structurally similar 3'-azido-3'-deoxythymidine (AZT) phosphoramidates 1-6 and 3'-fluoro-

59 sure of combination therapy with 3'-azido-3'-deoxythymidine (AZT) plus 2',3'-dideoxyinosine.

60 transcriptase (RT) give rise to 3'-azido-3'-deoxythymidine (AZT) resistance by a mechanism that has

61 erse transcriptase (RT) increase 3'-azido-3'-deoxythymidine (AZT) resistance in the context of thymid

62 on domain significantly increase 3'-azido-3'-deoxythymidine (AZT) resistance up to 536 times over wil

63 reverse transcriptase inhibitor 3'-azido-3'-deoxythymidine (AZT) suggest that reverse transcription

64 ncy virus type 1 is resistant to 3'-azido-3'-deoxythymidine (AZT) when four amino acid substitutions

65 HIV-2, resistance to zidovudine (3'-azido-3'-deoxythymidine (AZT)) and other NRTIs is conferred by mu

66 Previous studies have shown that 3'-azido-3'-deoxythymidine (AZT), (-)2',3'-dideoxy-3'-thiacytidine (

67 Another telomerase inhibitor, 3'-azido-3'-deoxythymidine (AZT), at a concentration that produced l

68 ctivity was more pronounced with 3'-azido-3'-deoxythymidine (AZT), in which 78% of the reaction produ

69 We sought to determine if 3'-azido-3'-deoxythymidine (AZT), the primary treatment for human im

70 in deciphering the mechanisms of 3'-azido-3'-deoxythymidine (AZT)-resistance by human immunodeficienc

71 an in vivo selection to identify 3'-azido-3'-deoxythymidine (AZT)-resistant mutants of rat DNA polyme

72 transcriptase (RT), such as the 3'-azido-3'-deoxythymidine (AZT)-resistant variant AZT-R (M41L/D67N/

73 A high-level 3'-azido-3'-deoxythymidine (AZT)-resistant variant containing delta

74 ction in p24 antigen produced by 3'-azido-3'-deoxythymidine (AZT)-sensitive HIV-1 isolates, A012 and

75 tase sensitivity to the inhibitor 3'-azido-3'deoxythymidine (AZT).

76 FIV mutant that is resistant to 3'-azido-3'-deoxythymidine (AZT).

77 terminating nucleoside inhibitor 3'-azido-3'-deoxythymidine (AZT).

78 ral used to treat HIV infection, 3'-azido-3'-deoxythymidine (AZT).

79 luoro-3'-thiacytidine (FTC), and 3'-azido-3'-deoxythymidine (AZT).

80 vity of the virus to zidovudine (3'-azido-3'-deoxythymidine; AZT).

81 rs for a hairpin that has six deoxyadenosine-deoxythymidine base pairs.

82 n clinical trials: beta-D-2',3'-didehydro-3'-deoxythymidine, beta-D-2'-ara-fluoro-2', 3'-dideoxyadeno

83 ation of the selective SND1 inhibitor 3', 5'-deoxythymidine bisphosphate (pdTp), inhibited tumor form

84 h unprotected nucleosides (e.g., 3'-azido-3'-deoxythymidine, cytidine, thymidine, uridine, inosine, o

85 cy virus (anti-HIV) agent 2',3'-didehydro-3'-deoxythymidine (D4T), like other 2',3'-dideoxynucleoside

86 ards the anti-HIV prodrug 2',3'-didehydro-3'-deoxythymidine (d4T).

87 The most potent was the 5'-phosphonate of 3'-deoxythymidine (ddT) (apparent Ki value of 63 nM).

88 3'-Azido-3'-deoxythymidine (AZT) and 3'-deoxythymidine (ddT) were chosen as models.

89 terization of an orthogonal NA kinase for 3'-deoxythymidine (ddT), using a new FACS-based screening p

90 ism of the deoxynucleoside monophosphates to deoxythymidine (dT) and deoxycytidine (dC), we hypothesi

91 lowing sequence: d(GCGACTTTTTGNCGC) [N = dU, deoxythymidine (dT) or 5-(3-aminopropyl)-2'-deoxyuridine

92 in complex with DNA containing a template 2'-deoxythymidine (dT) paired with an incoming dNTP or modi

93 ine (rA), cytidine (rC), guanosine (rG), and deoxythymidine (dT), and the nucleoside triphosphates AT

94 ation was used to provide separate peaks for deoxythymidine (dT), deoxyadenosine (dA), and deoxyguano

95 transfer of the gamma-phosphate of ATP to 2'-deoxythymidine (dThd) forming thymidine monophosphate (d

96 o increased circulating levels of thymidine (deoxythymidine, dThd) and deoxyuridine (dUrd) and has be

97 A probe consisting of a pair of deoxythymidines flanked by several 2'-O-methyl-modified

98 Two novel thymidine analogs, 3'-fluoro-3'-deoxythymidine (FLT) and 2',3'-didehydro-3'-deoxy-4'-eth

99 (AZT) phosphoramidates 1-6 and 3'-fluoro-3'-deoxythymidine (FLT) phosphoramidates 7-10 are reported.

100 cking proofreading activity, Kf (exo-), than deoxythymidine glycol triphosphate (dTgTP).

101 chniques to investigate the incorporation of deoxythymidine --> deoxyuridine (dT --> dU) substitution

102 ecamer d(CGCGAASSCGCG), where S = 4'-thio-2'-deoxythymidine, has converged at R=0.201 for 2605 reflec

103 e show through binding studies that a single deoxythymidine in a telomeric repeat dictates the DNA ve

104 ubated in aqueous solution with 5'-amino- 5'-deoxythymidine in the presence of N-(3-dimethylaminoprop

105 Inclusion of 3'-deoxythymidine in the scissile strand at position -1 per

106 rminus, possibly contributing to 3'-azido-3'-deoxythymidine inhibition.

107 When uridine and 2'-deoxythymidine ionization energies are evaluated, the re

108 nucleotides (ODNs) terminated by 5'-amino-5'-deoxythymidine is described.

109 me class (deoxycytidine, deoxyguanosine, and deoxythymidine kinases, as well as the multisubstrate dN

110 itro, HIV-1 mutants resistant to 3'-azido-3'-deoxythymidine (M41L/D67N/K70R/T215Y/K219Q) and (-)beta-

111 mechanism of synergy, beta-D-(+)-3'-azido-3'-deoxythymidine monophosphate (AZTMP) removal was examine

112 The deoxythymidine monophosphate (dTMP) substrate binding po

113 ucts, deoxycytidine monophosphate (dCMP) and deoxythymidine monophosphate (dTMP), prolongs the life s

114 is of both S-adenosylmethionine (AdoMet) and deoxythymidine monophosphate (dTMP), which are required

115 me responsible for the de novo production of deoxythymidine monophosphate and hence is crucial for DN

116 te synthase ThyX produces the DNA nucleotide deoxythymidine monophosphate from dUMP, using methylenet

117 he final step in the de novo biosynthesis of deoxythymidine monophosphate, dTMP, required for DNA rep

118 extended our previous study with 3'-azido-3'-deoxythymidine nucleotides and examined the effects on h

119 synthesis were synthesized from 3'-azido-3'-deoxythymidine or 3'-azido-2',3'-dideoxyuridine via acid

120 The commonly used 19mer with two deoxythymidine overhangs (19merTT) variant performed sim

121 23 of RB69 DNA polymerase intercalating into deoxythymidine primers.

122 Previously, we demonstrated that deoxythymidine release from degraded siRNAs reversed the

123 cceptor ODN extended by a single 5'-amino-5'-deoxythymidine residue at its 5'terminus.

124 GGTTGAC-3', where T* denotes the 5'-amino-5'-deoxythymidine residue.

125 ta67+T69G/L74I) leads to a novel 3'-azido-3'-deoxythymidine resistance motif and compensates for impa

126 AZT (3'-azido-3'-deoxythymidine) resistance involves the enhanced excisio

127 were enriched in poly-deoxyadenosine or poly-deoxythymidine sequences.

128 Chain-terminating 2'-3'-didehydro 3'-deoxythymidine [stavudine (D4T)] and 2'-3'-dideoxyinosin

129 the B form by 1.6 kcal/mol as compared with deoxythymidine, suggesting that the intrinsic conformati

130 f these modified nucleosides and 5'-amino-5'-deoxythymidine to the corresponding 5'-N-triphosphates t

131 nosine 5'-triphosphate (DXG-TP), 3'-azido-3'-deoxythymidine-TP, and 3TC-TP by using steady state kine

132 ng step in the pathway of helicase-catalyzed deoxythymidine triphosphatase (dTTPase) reaction is the

133 The nucleoside analogue 3'-azido-3'-deoxythymidine triphosphate (AZT-TP) had no effect, wher

134 of liver deoxyuridine triphosphate (dUTP) to deoxythymidine triphosphate (dTTP) was increased and cor

135 hange-inert nucleotide analogue rhodium(III) deoxythymidine triphosphate (Rh.dTTP) to investigate the

136 etylglucosamine-1-phosphate with uridine and deoxythymidine triphosphate (UTP and dTTP, respectively)

137 cleoside analogues indicated that 3'-azido-3'deoxythymidine triphosphate is much more inhibitory than

138 a fidelity and discrimination of 3'-azido-3'-deoxythymidine triphosphate substrates.

139 to several DNA repair pathways by providing deoxythymidine triphosphate that serve as precursors for

140 ase and deoxyuridine triphosphate instead of deoxythymidine triphosphate to reduce the risk of cross

141 in the hairpin dynamics upon the addition of deoxythymidine triphosphate.

142 ridine in tissues and elevated mitochondrial deoxythymidine triphosphate.

143 des with 5' overhangs of deoxyadenosines and deoxythymidines up to nine bases in length were used.

144 the amplified DNA product at positions where deoxythymidine would normally be incorporated at a frequ